Melatonin attenuates the development of antinociceptive tolerance to delta-, but not to mu-opioid receptor agonist in mice

Behavioural Brain Research

Volumn 182, Issue 1, 2007, Pages 21-27

  Dai, Xu ^a   Cui, Shi gang ^a   Li, Shi rong ^a   Chen, Qiang ^a   Wang, Rui ^a,b  

^a School of Life Sciences   (China)

^b HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

Author keywords

Deltorphin I; Endomorphin 1; Luzindole; Melatonin; Mice; Tolerance

Indexed keywords

DELTA OPIATE RECEPTOR AGONIST; DELTORPHIN; DELTORPHIN 1; ENDOMORPHIN 1; LUZINDOLE; MELATONIN; MELATONIN 2 RECEPTOR; MU OPIATE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG TOLERANCE; INHIBITION KINETICS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TAIL FLICK TEST; TREATMENT DURATION; TREATMENT OUTCOME;

ANALGESICS, OPIOID; ANALYSIS OF VARIANCE; ANIMALS; ANTIOXIDANTS; BEHAVIOR, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG TOLERANCE; INJECTIONS, INTRAVENTRICULAR; MALE; MELATONIN; MICE; MICE, INBRED STRAINS; NOCICEPTORS; OLIGOPEPTIDES; PAIN MEASUREMENT; PAIN THRESHOLD; RECEPTORS, OPIOID, DELTA; TRYPTAMINES;

EID: 34447278522     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbr.2007.04.018     Document Type: Article

References (45)

1. Bhargava H.N. Diversity of agents that modify opioid tolerance, physical dependence, abstinence syndrome, and self-administrative behavior. Pharmacol Rev 46 (1994) 293-324
2. Bilsky E.J., Inturrisi C.E., Sadee W., Hruby V.J., and Porreca F. Competitive and non-competitive NMDA antagonists block the development of antinociceptive tolerance to morphine, but not to selective mu or delta opioid agonists in mice. Pain 68 (1996) 229-237
3. Bodnar R.J., and Hadjimarkou M.M. Endogenous opiates and behavior: 2002. Peptides 24 (2003) 1241-1302
4. Bzdega T., Chin H., Kim H., Jung H.H., Kozak C.A., and Klee W.A. Regional expression and chromosomal localization of the delta opiate receptor gene. Proc Natl Acad Sci USA 90 (1993) 9305-9309
5. Cai Y., Zhang Y., Wu Y., and Pei G. Delta opioid receptor in neuronal cells undergoes acute and homologous desensitization. Biochem Biophys Res Commun 219 (1996) 342-347
6. Chang K.J., Wei E.T., Killian A., and Chang J.K. Potent morphiceptin analogs: structure activity relationships and morphine-like activities. J Pharmacol Exp Ther 227 (1983) 403-408
7. Dambisya Y.M., and Lee T.L. Role of nitric oxide in the induction and expression of morphine tolerance and dependence in mice. Br J Pharmacol 117 (1996) 914-918
8. Datta P.C., Sandman C.A., and Hoehler F.K. Attenuation of morphine analgesia by alpha-MSH, MIF-I, melatonin and naloxone in the rat. Peptides 3 (1982) 433-437
9. Dhanaraj E., Nemmani K.V., and Ramarao P. Melatonin inhibits the development of tolerance to U-50,488H analgesia via benzodiazepine-GABAAergic mechanisms. Pharmacol Biochem Behav 79 (2004) 733-737
10. Dhawan B.N., Cesselin F., Raghubir R., Reisine T., Bradley P.B., Portoghese P.S., et al. International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol Rev 48 (1996) 567-592
11. Dubocovich M.L. Luzindole (N-0774): a novel melatonin receptor antagonist. J Pharmacol Exp Ther 246 (1988) 902-910
12. El-Shenawy S.M., Abdel-Salam O.M., Baiuomy A.R., El-Batran S., and Arbid M.S. Studies on the anti-inflammatory and anti-nociceptive effects of melatonin in the rat. Pharmacol Res 46 (2002) 235-243
13. Emmerson P.J., Liu M.R., Woods J.H., and Medzihradsky F. Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes. J Pharmacol Exp Ther 271 (1994) 1630-1637
14. Esposti D., Lissoni P., Mauri R., Rovelli F., Orsenigo L., Pescia S., et al. The pineal gland-opioid system relation: melatonin-naloxone interactions in regulating GH and LH releases in man. J Endocrinol Invest 11 (1988) 103-106
15. Goldberg I.E., Rossi G.C., Letchworth S.R., Mathis J.P., Ryan-Moro J., Leventhal L., et al. Pharmacological characterization of endomorphin-1 and endomorphin-2 in mouse brain. J Pharmacol Exp Ther 286 (1998) 1007-1013
16. Golombek D.A., Escolar E., Burin L.J., De Brito Sanchez M.G., and Cardinali D.P. Time-dependent melatonin analgesia in mice: inhibition by opiate or benzodiazepine antagonism. Eur J Pharmacol 194 (1991) 25-30
17. Govitrapong P., Jitaijamjang W., Chetsawang B., Phansuwan-Pujito P., and Ebadi M. Existence and function of opioid receptors on mammalian pinealocytes. J Pineal Res 24 (1998) 201-208
18. Govitrapong P., Sawlom S., Chetsawang B., Sangchot P., and Ebadi M. The bovine pineal gland contains delta and mu but not kappa or ORL1 opioid receptor subtypes. Proc West Pharmacol Soc 45 (2002) 32-35
19. Govitrapong P., Sawlom S., and Ebadi M. The presence of delta and mu-, but not kappa or ORL(1) receptors in bovine pinealocytes. Brain Res 951 (2002) 23-30
20. Kest B., Jenab S., Brodsky M., Elliott K., and Inturrisi C.E. Supraspinal delta opioid receptor mRNA levels are not altered in [D-Ala2]deltorphin II tolerant mice. J Neurosci Res 39 (1994) 674-679
21. Kopp C., Vogel E., Rettori M.C., Delagrange P., Renard P., Lesieur D., et al. Antagonistic effects of S 22153, a new mt1 and MT2 receptor ligand, on the neophobia-reducing properties of melatonin in BALB/c mice. Pharmacol Biochem Behav 64 (1999) 131-136
22. Law P.Y., Hom D.S., and Loh H.H. Opiate regulation of adenosine 3′:5′-cyclic monophosphate level in neuroblastoma X glioma NG108-15 hybrid cells. Relationship between receptor occupancy and effect. Mol Pharmacol 23 (1983) 26-35
23. Leone M., D'Amico D., Moschiano F., Fraschini F., and Bussone G. Melatonin versus placebo in the prophylaxis of cluster headache: a double-blind pilot study with parallel groups. Cephalalgia 16 (1996) 494-496
24. Li S.R., Wang T., Wang R., Dai X., Chen Q., and Li R.D. Melatonin enhances antinociceptive effects of delta-, but not mu-opioid agonist in mice. Brain Res 1043 (2005) 132-138
25. Lissoni P., Esposti D., Esposti G., Mauri R., Resentini M., Morabito F., et al. A clinical study on the relationship between the pineal gland and the opioid system. J Neural Transm 65 (1986) 63-73
26. Morgan P.J., Barrett P., Howell H.E., and Helliwell R. Melatonin receptors: localization, molecular pharmacology and physiological significance. Neurochem Int 24 (1994) 101-146
27. Pang C.S., Tsang S.F., and Yang J.C. Effects of melatonin, morphine and diazepam on formalin-induced nociception in mice. Life Sci 68 (2001) 943-951
28. Raghavendra V., and Kulkarni S.K. Possible mechanisms of action in melatonin reversal of morphine tolerance and dependence in mice. Eur J Pharmacol 409 (2000) 279-289
29. Raghavendra V., and Kulkarni S.K. Reversal of morphine tolerance and dependence by melatonin: possible role of central and peripheral benzodiazepine receptors. Brain Res 834 (1999) 178-181
30. Roy S., Guo X., Kelschenbach J., Liu Y., and Loh H.H. In vivo activation of a mutant mu-opioid receptor by naltrexone produces a potent analgesic effect but no tolerance: role of mu-receptor activation and delta-receptor blockade in morphine tolerance. J Neurosci 25 (2005) 3229-3233
31. Shaji A.V., and Kulkarni S.K. Central nervous system depressant activities of melatonin in rats and mice. Indian J Exp Biol 36 (1998) 257-263
32. Shavali S., Ho B., Govitrapong P., Sawlom S., Ajjimaporn A., Klongpanichapak S., et al. Melatonin exerts its analgesic actions not by binding to opioid receptor subtypes but by increasing the release of beta-endorphin an endogenous opioid. Brain Res Bull 64 (2005) 471-479
33. Soignier R.D., Vaccarino A.L., Fanti K.A., Wilson A.M., and Zadina J.E. Analgesic tolerance and cross-tolerance to i.c.v. endomorphin-1, endomorphin-2, and morphine in mice. Neurosci Lett 366 (2004) 211-214
34. Tao P.L., Han K.F., Wang S.D., Lue W.M., Elde R., Law P.Y., et al. Immunohistochemical evidence of down-regulation of mu-opioid receptor after chronic PL-017 in rats. Eur J Pharmacol 344 (1998) 137-142
35. Tao P.L., Lee H.Y., Chang L.R., and Loh H.H. Decrease in mu-opioid receptor binding capacity in rat brain after chronic PL017 treatment. Brain Res 526 (1990) 270-275
36. Tao P.L., Lue W.M., Lee C.R., and Chang L.R. Alteration of the interaction of mu-opioid receptor and G protein after chronic PL017 treatment in rats. Chin J Physiol 38 (1995) 193-199
37. Tao P.L., Tsai C.L., Chang L.R., and Loh H.H. Chronic effect of [D-Pen2,D-Pen5]enkephalin on rat brain opioid receptors. Eur J Pharmacol 201 (1991) 209-214
38. Timar J., Gyarmati Z., and Furst Z. The development of tolerance to locomotor effects of morphine and the effect of various opioid receptor antagonists in rats chronically treated with morphine. Brain Res Bull 64 (2005) 417-424
39. Vanderah T.W., Ossipov M.H., Lai J., Malan Jr. T.P., and Porreca F. Mechanisms of opioid-induced pain and antinociceptive tolerance: descending facilitation and spinal dynorphin. Pain 92 (2001) 5-9
40. Vanecek J. Cellular mechanisms of melatonin action. Physiol Rev 78 (1998) 687-721
41. Waldhoer M., Bartlett S.E., and Whistler J.L. Opioid receptors. Annu Rev Biochem 73 (2004) 953-990
42. Yu C.X., Zhu B., Xu S.F., Cao X.D., and Wu G.C. The analgesic effects of peripheral and central administration of melatonin in rats. Eur J Pharmacol 403 (2000) 49-53
43. Yu C.X., Zhu C.B., Xu S.F., Cao X.D., and Wu G.C. Selective MT(2) melatonin receptor antagonist blocks melatonin-induced antinociception in rats. Neurosci Lett 282 (2000) 161-164
44. Zahn P.K., Lansmann T., Berger E., Speckmann E.J., and Musshoff U. Gene expression and functional characterization of melatonin receptors in the spinal cord of the rat: implications for pain modulation. J Pineal Res 35 (2003) 24-31
45. Zhao G.M., and Bhargava H.N. Effects of multiple intracerebroventricular injections of [D-Pen2,D-Pen5]enkephalin and [D-Ala2,Glu4]deltorphin II on tolerance to their analgesic action and on brain delta-opioid receptors. Brain Res 745 (1997) 243-247